EASL is delighted to announce the launch of Digital NAFLD Summit 2021, taking place 16–17 September. Let’s join forces to fight liver disease, together – focussing at this summit on non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
NAFLD is becoming a leading cause of end–stage liver disease worldwide, especially in individuals with features of metabolic syndrome. There is an urgent need to develop clinical management strategies to identify individuals at risk of liver events and to develop effective treatments to stop and even reverse liver damage. Significant progress has been made in the last years – in understanding the basis of NAFLD and of clinical heterogeneity, in monitoring liver disease in non-invasive ways, and in identifying novel therapeutic targets and promising treatments.
At Digital NAFLD Summit 2021, you will learn from the latest research on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) presented by top international experts. It will be a highly informative, engaging, and interactive summit, focused on current, evidence-based clinical practice, as key as advances in research that will shape the clinical practices of the future.
At this international summit, you can explore the science underlying the development of NAFLD, key biologies relevant to clinical translation, current clinical practice and patient engagement, from diagnosis and staging to selection, as well as the development, delivery, and monitoring of therapies.
Only by boosting awareness about NAFLD widely, among healthcare professionals, policymakers, the public, and patients, will we find solutions to address it. At EASL, we are committed to helping clinicians, researchers, and students network with the many and varied stakeholders in the field of hepatology, providing the opportunity to share research and learn from peers across Europe and beyond,
said Prof. Phil Newsome, EASL Secretary General
The modern lifestyle is taking a heavy toll on our overall health and organs in the body, and the liver is no exception. Globally, one in four people are living with fatty liver disease – with obesity, alcohol consumption, and sedentary lifestyles as key contributors. Learn about metabolic factors associated with liver disease, and how they interact with genetics, inflammation, and the gut–liver axis. Explore these influences, as well as promising new research in screening, monitoring, and treatment.
Calling upon you, our international, multi-generational network and employing a range of learning methods, we will draw inspiration from the evolution of science. Together.
At Digital NAFLD Summit 2021, we aim to present you with an update on the epidemiology and public health relevance of this condition, and on the debate on the most appropriate definition to identify individuals at higher risk of liver complications. Starting from the genetic, epigenetic, and metabolic basis of the disease, we will review the most recently discovered mechanisms underlying the pathogenesis of liver damage and the clinical heterogeneity of the disease.
Together at this summit, we will address key challenges in clinical practice and drug development. These challenges include: identifying biomarkers, imaging studies, and artificial intelligence-based approaches for patient risk stratification; identifying disease subsets with distinct features; and developing therapeutic targets to be tested in early and late phase clinical trials.
- Public health relevance of NAFLD
- Defining fatty liver disease, and the respective advantages of NAFLD vs MAFLD
- Genetic basis of NAFLD
- Clinical heterogeneity of NAFLD
- Pathogenesis of liver damage in NAFLD: from human genome and microbiome alterations to altered metabolism, intestinal permeability, immune system regulation, and liver fibrogenesis
- Current clinical management of NAFLD: challenges in driving lifestyle change and endoscopic/surgical therapy
- Progress in the non-invasive assessment of NAFLD: novel biomarkers, including genetic variants and lipid species, last–generation imaging approaches, and the implementation of machine–learning algorithms
- Identification of new therapeutic targets in preclinical models, including mitochondrial metabolism, state of the art in clinical trials in the field, and update on the design of therapeutic studies